Why Pharma and MedTech Companies Are Rethinking Their Strategy

The pharmaceutical and medical technology industries occupy an unusual position in the broader economy. They sit at the intersection of science, commerce, regulation, and human welfare — a combination that makes decision-making extraordinarily complex and the cost of getting it wrong extraordinarily high. And yet, despite this complexity, many organizations in these sectors continue operating with strategic frameworks and operational models designed for a very different era. That gap — between the pace of innovation and the pace of organizational adaptation — is where rigorous, forward-looking advisory has the most to contribute.

The pressures reshaping both industries are not new, but their intensity has grown considerably in recent years. Patent cliffs continue to erode revenue bases for established pharmaceutical players. Regulatory timelines have extended in several key markets while the cost of clinical development keeps rising. In medical technology, commoditization is accelerating in legacy product categories, and the shift toward connected, software-driven devices demands capabilities that most hardware-first organizations were simply not built to develop internally. Meanwhile, new entrants are moving quickly — digital health companies, AI-native startups, and cross-sector platforms are targeting segments that incumbents once considered safely protected.

The Pressure to Rethink Commercial Approaches

One of the most significant changes happening across both industries is the fundamental rethinking of the commercial model. The old approach — build a product, earn regulatory clearance, and push it through a traditional sales channel — is losing effectiveness across every major market. Payers are more selective than they were a decade ago. Formulary access is harder to achieve and easier to lose. Hospital procurement committees are more cost-conscious, and their decision-making processes involve a far broader set of stakeholders than previously. Patients, increasingly informed and empowered through digital access to clinical data, are asking questions that commercial representatives were not traditionally trained to answer.

This is the environment in which consulting pharma has taken on a meaningfully new dimension. Advisory engagements in the pharmaceutical space are no longer limited to market access strategy or launch sequencing. Today's most valuable advisory work happens earlier in the commercial process — at the point where development decisions are still actively being shaped. Which indication should be pursued first? Which patient population offers the strongest alignment between clinical benefit and commercial opportunity? How should a therapy be positioned in a market where existing treatments already have deeply established physician relationships? These questions, answered well before pivotal trial data arrives, shape the trajectory of a product across its entire commercial life, not just at launch.

Where Medical Technology Advisory Is Evolving

The evolution happening in pharmaceutical advisory is mirrored — and in some ways accelerated — in medical technology. Devices and diagnostics face a convergence of forces that are transforming both what products are expected to do and how they are evaluated by buyers, payers, and the health systems that deploy them. Connectivity, data generation, software integration, and outcome accountability are no longer premium features commanded by only the most sophisticated device categories. They are becoming baseline expectations across the entire spectrum of medical technology.

Med tech consulting has had to evolve accordingly. Where advisory in this space once centered primarily on regulatory strategy, product development timelines, and distribution channel optimization, it now encompasses a far broader and more nuanced set of organizational questions. How should a company structure its digital health infrastructure to complement and extend its physical devices? What evidence is required to demonstrate clinical value in a value-based purchasing environment where outcomes matter more than list price? How can a legacy medical device organization attract and retain the software engineering talent needed to compete in an increasingly software-defined market where its traditional hiring profiles no longer apply?

Strategy at the Organizational Level

The most important shift in advisory across both industries is the movement from product-centered to organization-centered strategy. In the past, most consulting engagements were scoped around a specific product, launch milestone, or regulatory event. The deliverable was a recommendation relevant to that single moment in the business cycle, and once the engagement concluded, the organization returned to its default operating mode.

That project-based approach still has its place — but the organizations creating the most durable competitive advantage are the ones receiving advisory that addresses deeper structural and cultural questions. How is the R&D function organized to maximize output while managing spend discipline? How is competitive intelligence being gathered, synthesized, and actually acted on by decision-makers at the right level? Is the organization designed to make consequential decisions at the pace the market now demands? Where are the talent gaps that will become operational risks within the next 18 months if left unaddressed?

Navigating Market Access and Reimbursement Complexity

Market access has become one of the most consequential and competitive battlegrounds for both pharmaceutical and medical technology companies. Health technology assessment bodies across Europe, reimbursement committees in Asia-Pacific markets, and formulary gatekeepers in the United States are applying more rigorous and comprehensive standards for clinical and economic evidence than they did five years ago. Organizations that engage with these processes reactively — submitting dossiers without a robust pre-launch evidence strategy — consistently underperform relative to those that integrate market access planning from the earliest stages of development.

This is another domain where consulting pharma engagements are delivering meaningful and measurable returns. Advisory teams that combine health economics expertise with regulatory strategy and commercial planning are helping pharmaceutical organizations build reimbursement narratives that are rigorously validated long before formal submission, substantially reducing uncertainty and accelerating time-to-coverage in priority markets.

For device companies navigating these same dynamics, med tech consulting engagements are helping leadership teams build integrated evidence strategies that address payer requirements, clinical validation standards, and health system procurement criteria within a single coordinated framework rather than as three separate workstreams that rarely share data or align on priorities.

Building Organizational Resilience

The companies succeeding in both industries share a common posture. They are not treating strategic advisory as a resource of last resort when internal teams hit a wall. They are treating external guidance as a continuous input — a mechanism for stress-testing assumptions, accelerating capability development, and staying genuinely connected to a landscape of competitive and regulatory change that does not slow down to wait for annual planning cycles. That posture, more than any specific methodology or tool, separates organizations navigating this environment with confidence from those that are perpetually reactive and perpetually catching up.